In the therapeutic context, the goal is to educate and direct the host’s immune system—particularly cytotoxic CD8+ T lymphocytes and helper CD4+ T cells—to specifically recognize tumor-derived antigens and eradicate malignant cells, including micrometastatic disease. The gene discussed is CD8A; the disease is neoplasm.